Following NCPE assessment of the company submission, alirocumab (Praluent®) is not considered cost effective for the treatment of primary hypercholesterolemia and mixed dyslipidemia and is therefore not recommended for reimbursement.

Following NCPE assessment Migalastat (Galafold®) is considered cost-effective and reimbursement is recommended subject to continuing availability of a patient access scheme.

Following NCPE assessment of the applicant’s submission, nivolumab is not considered cost effective as monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults and therefore is not recommended for reimbursement in the total population and not recommended for reimbursement at the submitted price for the clear cell population.

Following NCPE assessment of Trametinib (Mekinist®) it is not considered cost-effective and therefore not recommended for reimbursement at the submitted price.

Following NCPE assessment of daratumumab (Darzalex®) monotherapy, it is not considered cost-effective and therefore is not recommended for reimbursement.

Following NCPE assessment of mepolizumab (Nucala®) it is not considered cost-effective and therefore is not recommended for reimbursement at the submitted price.

Following NCPE assessment of the applicant’s submission, Obinutuzumab (Gazyvaro®) is not considered cost-effective at the submitted price.

The NCPE does not consider cobimetinib (Cotellic®) with vemurafenib (Zelboraf®) cost-effective for the treatment of advanced (unresectable or metastatic) melanoma with the BRAF V600 mutation and therefore it is not recommended for reimbursement at the submitted price.

The cost-effectiveness of human alpha-1 proteinase inhibitor (Respreeza®) has not been demonstrated and therefore is not recommended for reimbursement.

The cost effectiveness of elosulfase alfa (Vimizim®) has not been demonstrated. Therefore it is not recommended for reimbursement